PART Act
Summary
The PART Act, HR5221, mandates new motor vehicles to include catalytic converter identification, increasing manufacturing costs for all new vehicles sold in the U.S. This bill does not involve direct appropriations or immediate market shifts, but creates a new regulatory requirement for automakers. The bill is currently active, having been forwarded by a Subcommittee to a Full Committee by Voice Vote on 2026-02-10.
Key Takeaways
- 1.The PART Act (HR5221) mandates new catalytic converter identification on new vehicles, increasing manufacturing costs for automakers.
- 2.No direct funding is associated with this bill; the impact is regulatory, imposing new costs on manufacturers.
- 3.Automakers such as $GM, $F, $TM, $HMC, and $STLA will face increased production costs due to these new requirements.
Market Implications
The PART Act introduces a new regulatory cost for automakers, including $GM, $F, $TM, $HMC, and $STLA. While the current market data shows varied 30-day changes for these companies (e.g., $GM -3.64%, $F -5.92%, $TM -7.7%, $HMC -13.21%, $STLA +2.89%), these movements are not directly linked to the bill's progress. The bill's impact will be a long-term increase in manufacturing expenses, which could affect profit margins for these companies once implemented. Investors should monitor the bill's progression through the full committee and subsequent legislative stages for potential future impacts on these companies' financial outlooks.
Full Analysis
Market Impact Score
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
DRIVER Act
Respect NATO Allies Act
Streamlining Federal Grants Act of 2026
Strong Start Act
Working Families Flexibility Act of 2025
To require the Secretary of State, in consultation with the Secretary of Health and Human Services and other relevant departments and agencies, as appropriate, to formulate a strategy for the Federal Government to secure support from foreign countries, multilateral organizations, and other appropriate entities to facilitate the development and commercialization of qualified pandemic or epidemic products, and for other purposes.
Deterring Adversarial Access to Americans’ Data Act
ACE Agriculture Act